![[Matthew Mobergs avatar]](https://franklintempletonprod.widen.net/content/gmthnin2t2/webp/Moberg_Matthew_500x500.png){kind=avatar}
Managed Fund Since 2020
Equity Active
HELX Franklin Genomic Advancements ETF
- Forefront of genomic innovation. Invests in companies that are driving advancements in DNA sequencing, gene editing and personalized medicine, paving the way for groundbreaking health care solutions.
- Research-driven. Uses bottom-up fundamental analysis conducted by a dedicated, industry-specific team to identify disruptive business models at the right stage for investment.
- Innovation expertise. Actively managed by a seasoned portfolio management team that is based in Silicon Valley.
Popular Documents
Overview
Fund Facts
Fund description
The fund seeks capital appreciation by investing in equity securities inside and outside of the United States, including developing or emerging markets. The fund invests in companies that are relevant to its investment theme of genomic advancements that the investment manager believes are substantially focused on/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business.
- Benchmark
- Russell 3000 Index
- Fund Inception Date
- 02/25/2020
- Listing Exchange
- Cboe
Identifiers
- Ticker
- HELX
- CUSIP Code
- 35473P520
- ISIN Code
- US35473P5200
- Bloomberg Code
- HELX US
Average Annual Total Returns As of 09/30/2025
- -4.50%1 Year
- 1.43%3 Years
- -2.42%5 Years
- —10 Years
- 3.96%Since Inception
02/25/2020
Performance data quoted represents past performance, which does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the figures shown.
Top Sectors
As of 10/29/2025 % of Total (Updated Daily)
Additional Fund Info
- Fiscal Year End
- March 31
- ETF Type
- Active
- Morningstar Category
- Health
Trading Characteristics
- Shares Outstanding
- 600,000
- Daily Volume
- 188
- 20-Day Average Volume
- 2685.45
Manager and Commentary
About the Team
Franklin Equity Group
Growth equity managers with a focus on in-depth fundamental research, we offer expertise in managing global, U.S. and sector-specific strategies across the market capitalization spectrum. Our center of gravity in Silicon Valley allows us to follow companies across their private to public life cycles, developing deeper insights into future industry trends and identifying potential disruptors.
Franklin Equity Group
Latest Insights
October 13, 2025
October 1, 2025
October 1, 2025
Performance
Calendar Year Returns
As of 09/30/2025
Performance data quoted represents past performance, which does not guarantee future results. Current performance may be lower or higher than the figures shown. Principal value and investment returns will fluctuate, and investors' shares, when redeemed, may be worth more or less than the original cost. Returns are based on Market Price or NAV, assume the reinvestment of all distributions and the deduction of all Fund expenses. Performance would have been lower if expenses had not been waived in various periods. Returns for periods of less than one year are not annualized.
Franklin Genomic Advancements ETF - Market Price Return (%)
Franklin Genomic Advancements ETF - NAV Return (%)
Russell 3000 Index (%)
Ratings 7
©2025 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Portfolio
Assets
As of11/02/2025 (Updated Daily)
- Total Net Assets
- $21.14 Million
Positions
As of 10/30/2025 (Updated Daily)
Number of Holdings
- Fund
- 66
Portfolio Statistics
As of 10/30/2025 (Updated Daily)
Weighted Average Market Capitalization (USD)
- Fund
- $52.15 Billion
Market Capitalization Allocation
As of 10/30/2025 % of Equity (Updated Daily)
| Market Capitalization | Fund |
|---|---|
| <2.0 Billion | 2.76% |
| 2.0-5.0 Billion | 16.97% |
| 5.0-10.0 Billion | 9.04% |
| 10.0-25.0 Billion | 29.39% |
| 25.0-50.0 Billion | 20.46% |
| >50.0 Billion | 21.38% |
Holdings
As of 10/31/2025 (Updated Daily)
GUARDANT HEALTH INC
NATERA INC
INSMED INC
MEDPACE HOLDINGS INC
ALNYLAM PHARMACEUTICALS I
KRYSTAL BIOTECH INC
SAMSUNG BIOLOGICS CO LTD
ADAPTIVE BIOTECHNOLOGIES
TEMPUS AI INC
BRIDGEBIO PHARMA INC
Distributions & Tax
- Distribution Frequency
- AnnuallyThis fund is an ex-Dividend fund
- Capital Gain Distributions
- December
Distributions are not guaranteed and are subject to change.
Final composition of the current year’s distribution—income, capital gains and/or return of capital—are based on US tax rules and will be determined by February of the following year. For tax characterization of a distribution, such as return of capital and tax-exempt income, click on the “Tax Information” tab above.
Distributions Per Share
12/31/2021
12/14/2021
Annually, a fund must distribute all realized capital gains net of realized losses, so the fund will not be subject to an entity level income tax. A fund’s capital gain distribution in a particular year may be a result of the disposition of holdings that appreciated in value during prior years. Thus, while the fund may gain or lose value over the course of a year, a capital gain distribution paid by the fund may not be indicative of current performance of the fund.
The distributable amount of net capital gains are paid on a per-share basis to all investors who hold shares of the fund on the record date of the distribution and are recognized by the shareholder for tax purposes as of the ex-date of the distribution, regardless of when the gains or losses arose in the fund. Net gains on holdings held long term by the fund would be distributed to shareholders as a long-term capital gain distribution no matter how long the shareholder has owned shares in the fund.
Refer to the fund’s annual report or statement of additional information for specific information regarding distributions.
Pricing
Premium/Discount Analysis 5
As of 09/30/2025 (Updated Quarterly)
Premium / Discount
- Total Days in Period
- 64
- Days at NAV
- 13
- Days at Premium
- 36
- Days at Discount
- 15
- Greatest Premium
- $0.36
- Greatest Discount
- $-0.03
| Premium/Discount Analysis | Breakdown |
|---|---|
| 0% to 0.5% | 36 days |
| 0.0% | 13 days |
| -0.5% to 0% | 15 days |
Historical Premium/Discount 6
As of 10/31/2025 (Updated Daily)
Documents
Fund Literature
| Name | Download | Add to Cart | |
|---|---|---|---|
| Factsheet - Franklin Genomic Advancements ETF |
Regulatory Documents
| Name | Download | Add to Cart | |
|---|---|---|---|
| Annual Report - Franklin Genomic Advancements ETF - Single Class | |||
| Annual Financial Statements and Other Information - Franklin Templeton ETF Trust 2 | |||
| Semi-Annual Report - Franklin Genomic Advancements ETF - Single Class | |||
| Semi-Annual Financial Statements and Other Information - Franklin Income Equity Focus ETF | |||
| Prospectus - Franklin Templeton ETF Trust 2 Active Funds | |||
| Summary Prospectus - Franklin Genomic Advancements ETF | |||
| Statement of Additional Information - Franklin Templeton ETF Trust 2 Active Funds | |||
| Fiscal Q1 Holdings - Franklin Templeton ETF Trust Smart Beta Funds | |||
| Fiscal Q3 Holdings - Franklin Templeton ETF Trust Smart Beta Funds |
Risks
All investments involve risks, including possible loss of principal. Equity securities are subject to price fluctuation and possible loss of principal. The fund’s investment strategies incorporate the identification of thematic investment opportunities, and its performance may be negatively impacted if the investment manager does not correctly identify such opportunities or if the theme develops in an unexpected manner. By focusing its investments in health care-related industries, the fund carries much greater risks of adverse developments and price movements in such industries than a fund that invests in a wider variety of industries. International investments are subject to special risks, including currency fluctuations and social, economic and political uncertainties, which could increase volatility. These risks are magnified in emerging markets. The portfolio is non-diversified and may invest in a relatively small number of issuers, which may negatively impact the fund's performance and result in greater fluctuation in the value of the fund's shares. The manager may consider environmental, social and governance (ESG) criteria in the research or investment process; however, ESG considerations may not be a determinative factor in security selection. In addition, the manager may not assess every investment for ESG criteria, and not every ESG factor may be identified or evaluated. When the fund’s size is small, the fund may experience low trading volume and wide bid/ask spreads. These and other risks are discussed in the fund’s prospectus.
Important Information
Franklin Distributors, LLC. Member FINRA, SIPC. All entities mentioned are Franklin Templeton affiliated companies. Investment Products: NOT FDIC INSURED | NO BANK GUARANTEE | MAY LOSE VALUE.
Reports and other information about the funds are available on the EDGAR Database on the SEC's Internet site at www.sec.gov.
You need Adobe Acrobat Reader to view and print PDF documents. Download a free version from Adobe's website.
Important data provider notices and terms available at www.franklintempletondatasources.com.
Performance data quoted represents past performance, which does not guarantee future results.
CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.
Indexes are unmanaged and one cannot invest directly in an index. They do not reflect any fees, expenses or sales charges.
All investments involve risk, including possible loss of principal. Please see each product's web page for specific details regarding investment objective, risks, performance, and other important information. Review this information carefully before you make any investment decision. Investors cannot invest directly in an index, and unmanaged index returns do not reflect any fees, expenses or sales charges.
Carefully consider a fund’s investment objectives, risks, charges and expenses before investing. Please view the prospectus or summary prospectus for this and other information. Read it carefully.
Franklin Templeton, its affiliated companies, and its employees are not in the business of providing tax or legal advice to taxpayers. These materials and any tax-related statements are not intended or written to be used, and cannot be used or relied upon, by any such taxpayer for the purpose of avoiding tax penalties or complying with any applicable tax laws or regulations. Tax-related statements, if any, may have been written in connection with the “promotion or marketing” of the transaction(s) or matter(s) addressed by these materials, to the extent allowed by applicable law. Any such taxpayer should seek advice based on the taxpayer’s particular circumstances from an independent tax advisor.
ETFs trade like stocks, fluctuate in market value and may trade at prices above or below their net asset value. Brokerage commissions and ETF expenses will reduce returns. ETF shares may be bought or sold throughout the day at their market price (MP), not their Net Asset Value (NAV), on the exchange on which they are listed. Shares of ETFs are tradable on secondary markets and may trade either at a premium or a discount to their NAV on the secondary market. Prior to trading in the secondary market, shares of the fund are "created" at NAV by market makers, large investors and institutions only in block-size Creation Units. Each "creator" or "Authorized Participant" enters into an authorized participant agreement with Franklin Distributors, LLC. Only an Authorized Participant may create or redeem Creation Units directly with the fund. Retail investors buy and sell shares of ETFs at market price (not NAV) in the secondary market throughout the trading day. These shares are not individually available for purchase or redemption directly from the ETF.
Franklin Distributors, LLC serves as the distributor of Creation Units for the ETFs on an agency basis. Franklin Distributors, LLC does not maintain a secondary market in the funds' shares.
Redemption payments will be effected within the specified number of calendar days following the date on which a request for redemption in proper form is made. For more information, please see the ETF’s statement of additional information (SAI) which can be found on the fund’s webpage.
The Russell 3000 Index measures the performance of the 3,000 largest U.S. companies based on total market capitalization.
Source: FTSE.